Indaptus Therapeutics, Inc.
Status: Publicly traded
Last reviewed: October 2026
Direct answer
Indaptus Therapeutics, Inc. is publicly traded on NASDAQ under the ticker INDP.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as...
Can you invest in Indaptus Therapeutics, Inc.?
Yes. Indaptus Therapeutics, Inc. trades publicly on NASDAQ as INDP.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Indaptus Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.